Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL

Introduction: Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is authorized for the treatment of chronic lymphocytic leukemia (CLL). This study aims to explore the cardiac safety profile of ibrutinib in comparison with obinutuzumab.Methods: A retrospective pharmacovigilance study was conducte...

Full description

Bibliographic Details
Main Authors: Annamaria Mascolo, Raffaella Di Napoli, Nunzia Balzano, Elena D’Alessio, Imma Izzo, Francesco Rossi, Giuseppe Paolisso, Annalisa Capuano, Liberata Sportiello
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Pharmacology
Subjects:
ibrutinib
obinutuzumab
chronic lymphocytic leukemia
cardiovascular safety
pharmacovigilance
real-world data
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1229304/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1229304/full

Similar Items